Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
12.29
-1.31 (-9.60%)
At close: Apr 1, 2025, 4:00 PM
12.21
-0.08 (-0.65%)
After-hours: Apr 1, 2025, 7:23 PM EDT
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
422
Market Cap
1.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | 335.66M | 308.98M | 1,158.19% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
DNLI News
- 5 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 12 days ago - Denali Therapeutics: Vast Pipeline, First Approval Up Ahead - Seeking Alpha
- 4 weeks ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 7 weeks ago - Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewsWire
- 2 months ago - Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
- 2 months ago - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains - Seeking Alpha
- 3 months ago - Denali Therapeutics ALS drug fails in mid-stage trial - Reuters
- 3 months ago - Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire